PUBLISHER: Allied Market Research | PRODUCT CODE: 1472297
PUBLISHER: Allied Market Research | PRODUCT CODE: 1472297
The global testosterone replacement therapy market was valued at $1.9 billion in 2022, and is projected to reach $2.9 billion by 2032, growing at a CAGR of 4.2% from 2023 to 2032.
Testosterone replacement therapy is a medical intervention designed to address low levels of testosterone. Testosterone is a crucial hormone responsible for the development of male reproductive tissues and the maintenance of male characteristics, such as muscle mass, bone density, and facial hair. As men age, testosterone levels tend to decline naturally, leading to various symptoms such as fatigue, reduced libido, and loss of muscle mass. Testosterone replacement therapy involves the administration of exogenous testosterone through methods such as injections, patches, gels, or pellets implanted under the skin. The goal is to restore testosterone levels to a normal range and alleviate associated symptoms.
The testosterone replacement therapy market growth is attributed rise in prevalence of hypogonadism and the rising incidence of chronic diseases such as obesity, diabetes, and metabolic syndrome, which are associated with an increased risk of low testosterone levels. The prevalence of hypogonadism has witnessed a notable rise in recent years, emerging as a significant driver for the growth of testosterone replacement therapy market. Hypogonadism, characterized by the insufficient production of testosterone in the testes, affects a considerable portion of the male population, particularly as they age. For instance, according to 2021 report by National Library of Medicine, it was estimated that the prevalence of hypogonadism in middle-aged and older men varies between 2.1% and 38.7%. Testosterone replacement therapy has become a primary choice for healthcare professionals in addressing the hormonal imbalances associated with hypogonadism. Thus, a rise in prevalence of hypogonadism is expected to drive the growth of the market.
In addition, rise in incidence of chronic diseases such as obesity and diabetes which causes low testosterone is expected to drive the market growth. Chronic diseases, including diabetes, obesity, and cardiovascular ailments, have become increasingly prevalent worldwide, contributing to a surge in individuals experiencing hormonal imbalances, particularly low testosterone levels. Scientific studies have established a direct correlation between chronic illnesses and reduced testosterone production, creating a substantial patient pool seeking effective therapeutic interventions to treat low testosterone levels. According to 2023 report by National Library of Medicine, it was reported that male obesity is linked to hormonal disturbances leading to impaired gonadal functions, both hormonal and reproductive. Male obesity-related hypogonadism has been reported in up to 45% of patients with moderate to severe obesity. Thus, rise in incidence of chronic diseases, such as obesity and diabetes, is expected to drive the growth of the testosterone replacement therapy market. However, side effects associated with the chemical peels and photo therapy restrain the growth of the market. According to the 2023 report by American College of Cardiology Foundation, it was reported that the incidence of pulmonary embolism, nonfatal arrhythmia, atrial fibrillation, and acute injury was higher in subjects who received testosterone replacement therapy.
The testosterone replacement therapy market is segmented on the basis of product type, active ingredient, end user, and region. By product type, the market is classified into injectables, topical, and others. Other product types include oral, implant, and intranasal formulations. By active ingredient, the market is divided into testosterone cypionate, testosterone, testosterone enanthate, testosterone undecanoate, others. By end user, it is segregated into hospitals, and clinics. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA).
Major key players that operate in the testosterone replacement therapy market are AbbVie Inc, Besins Healthcare SA, Acerus Pharmaceuticals Corporation, Amneal Pharmaceuticals Inc., Acrux Ltd., Endo International Plc, Biote Medical, LLC, Pfizer Inc., Insud Pharma S.L, and Marius Pharmaceuticals. Key players have adopted acquisition as a key developmental strategy to improve the product portfolio of the testosterone replacement therapy market
Additional benefits you will get with this purchase are:
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)